Acasti Pharma Announces Pricing for its Public Offering of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
104
Acasti Pharma Announces Pricing for its Public Offering of Units

LAVAL, QUÉBEC--(Marketwired - Feb. 10, 2017) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

February 10, 2017 - Acasti Pharma Inc. (" Acasti ", " Acasti Pharma " or the " Corporation ") (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that it has received a receipt for a final short form prospectus (the " Final Prospectus ") in connection with its previously announced public offering of units (" Units "). The Corporation has also entered into an agency agreement with Echelon Wealth Partners Inc., as sole bookrunner and lead agent (the " Agent "), pursuant to which the Agent will offer, on a "commercially reasonable best efforts" basis, the Units for minimum gross proceeds of CAD$4,500,000 (the " Minimum Offering ") and maximum gross proceeds of CAD$8,000,000 (the " Maximum Offering " and, collectively with the Minimum Offering, the " Offering "). Further, Leede Jones Gable Inc. has been appointed as a selling group member.

Each Unit will consist of one Class A share in the capital of the Corporation (a " Common Share ") and half of one Common Share purchase warrant (each whole Common Share purchase warrant, a " Warrant "), at a price of CAD$1.45 per Unit. Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of CAD$2.15 per Common Share, subject to adjustment in certain circumstances, at any time prior to 5:00 p.m. (Montreal time) on the date that is five years following the closing of the Offering, subject to the acceleration of the expiry date in certain circumstances.

In consideration for the services rendered by the Agent under the Offering, the Agent will receive a cash commission equal to 7% of the gross proceeds of the Offering. The Agent will also receive broker warrants (the " Broker Warrants ") to purchase, in the aggregate, up to that number of Common Shares equal to 7% of the number of Units issued under the Offering. Each Broker Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD$2.15 per Common Share, at any time prior to 5:00 p.m. (Montreal time) on the date that is 12 months following the closing of the Offering.

The Offering and the Corporation's previously announced private placement of $2 million aggregate principal amount of unsecured convertible debentures and warrants (collectively, the " Private Placement ") are expected to close concurrently on or about of February 21, 2017, subject to certain conditions, including, but not limited to, final approval of the TSX Venture Exchange and the NASDAQ Stock Market.

If the Minimum Offering and Private Placement are completed, the Corporation intends to use the net proceeds therefrom to fund its operations through December 31, 2017 to complete its manufacturing scale-up and the planning for the Phase 3 clinical trial for CaPre® (omega-3 phospholipid), Acasti's lead product candidate. In the event the Maximum Offering and Private Placement are completed, the Corporation intends to use the net proceeds therefrom to additionally complete the initiation of the Phase 3 clinical trial and begin its patient enrollment. Net proceeds from the Offering and Private Placement are also planned to be used for intellectual property expansion, business development activities, general and administrative expenses, and working capital.

A copy of the Final Prospectus, which was filed in each of the provinces of Alberta, British Columbia, Manitoba, Ontario and Québec, contains important information relating to the Offering and the Units, and is available on SEDAR at www.sedar.com or by contacting the Agent, at (416) 479-7370 or ecm@echelonpartners.com . Investors should read the Final Prospectus before making an investment decision.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the " U.S. Securities Act ") or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of any offer to buy the securities in the United States, in any province or territory of Canada or in any other jurisdiction. There shall be no sale of the securities in any jurisdiction in which an offer to sell, a solicitation of an offer to buy or sale would be unlawful.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The Corporation's strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com .

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking information in this press release includes, but is not limited to, information or statements about the completion and expected timing of the Private Placement and the Offering; whether the terms of the Private Placement or the Offering will be as described in this press release; whether the Offering and Private Placement will be successful; the receipt of required regulatory approvals (including stock exchange) in respect of the Private Placement and the Offering; the net proceeds from the Private Placement and the Offering, Acasti's use of the net proceeds from the Private Placement and the Offering and the results of activities conducted using such net proceeds. There can be no assurance as to whether or when the Offering and Private Placement may be completed, or as to the actual size or terms of the Offering or Private Placement.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement, the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F and which is available on SEDAR at www.sedar.com , on EDGAR at www.sec.gov/edgar/shtml and on the investor section of Acasti's website at www.acastipharma.com (the " AIF ") and the "Forward-Looking Information" section contained in the Amended and Restated Preliminary Prospectus, which is available on SEDAR at www.sedar.com . All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions, including, without limitation, the failure to receive regulatory approvals (including stock exchange) or otherwise satisfy the conditions to the completion of the Private Placement and the Offering in the time frame anticipated and the funds thereof not being available to the Corporation. Certain important assumptions by Acasti in making forward-looking statements include, but are not limited to the satisfaction of all conditions to completion of the Private Placement and the Offering in the time frame anticipated; the receipt of required regulatory approvals (including stock exchange approvals) and successful completion of the Private Placement and the Offering on the terms described in this press release, if at all, in the time frame anticipated. Additional information about these assumptions and risks and uncertainties is contained in the AIF and the Final Prospectus, in each case under the heading "Risk Factors."

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact: Jan D'Alvise Chief Executive Officer 450-686-4555 info@acastipharma.com www.acastipharma.com Media & Investor Contact: Jessica Dyas Canale Communications 619-849-5385 jessica@canalecomm.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 19

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 13

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 11

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 6

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 5

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 12

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 14

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 28

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 64

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 40 Years: The Evolution of Fudan SoM

Updated Category News Views 275

Fudan SoM Celebrates a Milestone in Business Education The Fudan University School of Management recently celebrated its 40th anniversary with great enthusiasm, showcasing a commitment to fostering global business education. This significant event coincided with the launch of the 2025 Global Business Education Deans' Forum and Expo, a pivotal gathering that highlights...

Continue Reading
ICU Medical Stock Hits Record Low: What Investors Should Know

Updated Category News Views 321

ICU Medical Faces Significant Market Challenges Amidst a turbulent market landscape, ICU Medical (NASDAQ: ICUI) has witnessed its stock price decline to a 52-week low of $1.69, resulting in a market capitalization plummeting to approximately $7.65 million. The company’s substantial dip in value, which is around -86.22% over the past year, highlights a significant...

Continue Reading
Sagimet Biosciences Unveils Comprehensive Financial Results and Milestones

Updated Category News Views 178

Sagimet Biosciences Shares 2024 Financial Highlights Sagimet Biosciences Inc. (NASDAQ: SGMT), a prominent clinical-stage biopharmaceutical firm focusing on innovative therapies for metabolic and fibrotic disorders, recently revealed its financial outcomes for the full year ended December 31, 2024. With notable advancements in their drug pipeline, Sagimet is...

Continue Reading
Exploring the Expanding Opportunities in Cannabidiol Market

Updated Category News Views 158

Cannabidiol Market Growth Projections The global cannabidiol (CBD) market is a rapidly evolving sector that is transforming the healthcare landscape. With increasing recognition of its therapeutic potential, the market was valued at approximately USD 8.97 billion in 2024 and is set to reach an impressive USD 38.97 billion by 2034. This remarkable growth, projected at a...

Continue Reading
Kelley Morris Appointed President of Hospital Foundations

Updated Category News Views 476

Kelley Morris Steps into Leadership Role The Memorial and Joe DiMaggio Children's Hospital Foundations have made a significant change in leadership by appointing Kelley Morris, MHA, as President and CEO. With an impressive background spanning over 25 years in healthcare philanthropy, operations, and research administration, Morris is set to lead the Foundations in...

Continue Reading